Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Baiya SARS-CoV-2 Vax 2 in Healthy Adults
NCT05197712Phase 1Unknown
- Sponsor
- Baiya Phytopharm
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Baiya SARS-CoV-2 Vax 2 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Baiya Phytopharm. Primary endpoints: Frequency and grade of solicited local and systemic reactogenicity Adverse Events, Frequency and grade of Adverse Events and 3 more. Status: unknown.
02
Drugs
Baiya SARS-CoV-2 Vax 2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05197712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197712.